This company has been marked as potentially delisted and may not be actively trading. Amedica (AMDA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock AMDA vs. INFU, NSPR, CTCX, HSAQ, TMDIF, GBS, RVP, PETV, BTCY, and NUROShould you be buying Amedica stock or one of its competitors? The main competitors of Amedica include InfuSystem (INFU), InspireMD (NSPR), Carmell (CTCX), Health Sciences Acquisitions Co. 2 (HSAQ), Titan Medical (TMDIF), GBS (GBS), Retractable Technologies (RVP), PetVivo (PETV), Biotricity (BTCY), and NeuroMetrix (NURO). These companies are all part of the "medical" sector. Amedica vs. Its Competitors InfuSystem InspireMD Carmell Health Sciences Acquisitions Co. 2 Titan Medical GBS Retractable Technologies PetVivo Biotricity NeuroMetrix InfuSystem (NYSE:INFU) and Amedica (NASDAQ:AMDA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership. Does the media prefer INFU or AMDA? In the previous week, InfuSystem's average media sentiment score of 0.00 equaled Amedica'saverage media sentiment score. Company Overall Sentiment InfuSystem Neutral Amedica Neutral Is INFU or AMDA more profitable? InfuSystem has a net margin of 1.12% compared to Amedica's net margin of -139.62%. InfuSystem's return on equity of 2.78% beat Amedica's return on equity.Company Net Margins Return on Equity Return on Assets InfuSystem1.12% 2.78% 1.41% Amedica -139.62%-148.60%-67.83% Which has stronger earnings & valuation, INFU or AMDA? InfuSystem has higher revenue and earnings than Amedica. Amedica is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInfuSystem$137.58M0.94$870K$0.1444.00Amedica$11.23M3.54-$9.32M-$3.13-1.07 Do analysts recommend INFU or AMDA? InfuSystem currently has a consensus target price of $13.00, suggesting a potential upside of 111.04%. Given InfuSystem's stronger consensus rating and higher possible upside, equities research analysts plainly believe InfuSystem is more favorable than Amedica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InfuSystem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 4.00Amedica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals hold more shares of INFU or AMDA? 71.1% of InfuSystem shares are owned by institutional investors. Comparatively, 3.7% of Amedica shares are owned by institutional investors. 11.4% of InfuSystem shares are owned by company insiders. Comparatively, 0.9% of Amedica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, INFU or AMDA? InfuSystem has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Amedica has a beta of -1.24, indicating that its share price is 224% less volatile than the S&P 500. SummaryInfuSystem beats Amedica on 13 of the 14 factors compared between the two stocks. Get Amedica News Delivered to You Automatically Sign up to receive the latest news and ratings for AMDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMDA vs. The Competition Export to ExcelMetricAmedicaSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.76M$255.90M$5.54B$9.05BDividend YieldN/AN/A5.24%4.03%P/E Ratio-1.075.9227.4320.23Price / Sales3.5473.84420.79118.64Price / CashN/A196.1236.8958.07Price / Book1.866.128.045.67Net Income-$9.32M-$27.18M$3.18B$249.13M Amedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMDAAmedicaN/A$3.35+0.6%N/A-28.0%$39.76M$11.23M-1.07N/AINFUInfuSystem1.9498 of 5 stars$6.50+1.5%$13.00+100.2%N/A$136.50M$137.58M108.27410NSPRInspireMD3.233 of 5 stars$2.240.0%$4.50+101.0%-7.6%$68.56M$7.03M-2.9850High Trading VolumeCTCXCarmellN/A$2.57-12.0%N/A+40.2%$53.73M$32.84K0.0014News CoverageHSAQHealth Sciences Acquisitions Co. 2N/A$3.22+3.9%N/A-62.0%$36.10MN/A0.004TMDIFTitan MedicalN/A$0.29-6.4%N/A+675.6%$32.51M$17.63M-0.2350GBSGBSN/A$1.78-2.7%N/A-3.3%$26.50M$440K-3.187RVPRetractable Technologies2.1182 of 5 stars$0.66+0.8%N/A-43.9%$19.85M$33.75M-1.23240Gap DownPETVPetVivoN/A$0.77-2.5%N/A+65.3%$18.68M$1.05M-1.7120Gap DownHigh Trading VolumeBTCYBiotricityN/A$0.47+24.9%N/A-46.5%$11.83M$12.06M-0.4440News CoverageGap DownNURONeuroMetrixN/A$4.55+4.4%N/A+22.0%$9.37M$3.03M-0.9920High Trading Volume Related Companies and Tools Related Companies InfuSystem Competitors InspireMD Competitors Carmell Competitors Health Sciences Acquisitions Co. 2 Competitors Titan Medical Competitors GBS Competitors Retractable Technologies Competitors PetVivo Competitors Biotricity Competitors NeuroMetrix Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMDA) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amedica Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMDA Stock Alerts